研究者情報   
   検索ページ


    (最終更新日:2017-10-10 14:47:42)
  ツダ タカシ   TSUDA TAKASHI
  津田享志
   所属   医学部医学科 臨床腫瘍学
   職種   講師
■ 学術雑誌
1. 総説  Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy 2017/09
2. 原著  Identification of FGFR3-TACC3 fusion in esophageal cancer 2017/02
3. 原著  Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison. 2016/04
4. 原著  Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/04
5. 原著  Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/01
全件表示(26件)
■ 学会発表
1. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer  2017/07/27
2. Identification of a FGFR3-TACC3 fusion in esophageal cancer  2017/04/01
3. "Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients
with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and
oxaliplatin (L-OHP) chemotherapy: WJOG6510G."  2017/01
4. Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): validation in the phase III WJOG4407G trial  2017/01
5. 当院のIO副作用対策チームの取り組み (シンポジウム・ワークショップ・パネルディスカッション等) 2016/07/29
全件表示(34件)